The India idiopathic pulmonary fibrosis treatment market size reached USD 31.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 62.2 Million by 2033, exhibiting a growth rate (CAGR) of 7.48% during 2025-2033.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 31.4 Million |
Market Forecast in 2033
|
USD 62.2 Million |
Market Growth Rate 2025-2033 | 7.48% |
Idiopathic pulmonary fibrosis (IPF) refers to an infectious lung disease that causes the buildup of scar tissues in the lungs, which reduces their oxygen-carrying functionalities. It is diagnosed through various chest imaging evaluations, including lung biopsies, antibody tests, and pulmonary function tests. IPF is treated by prescribing anti-fibrotic drugs containing nintedanib and pirfenidone salts, which slows the rate of scar tissue formation and controls the associated symptoms. Supportive therapeutic options, including palliative care and oxygen therapy, are also provided as effective treatment methods for IPF.
The increasing prevalence of fibrotic diseases, especially in the geriatric population, is primarily fueling the India IPF treatment market growth. The rising awareness regarding the availability of effective strategies for preventing and managing IPF is acting as another growth-inducing factor. In line with this, rapid economic growth and advancements in diagnostic and treatment methods are further propelling the market growth. Moreover, extensive research and development (R&D) activities for introducing novel medications and increasing improvements in the healthcare infrastructure are positively influencing the market growth across the country.
IMARC Group provides an analysis of the key trends in each segment of the India idiopathic pulmonary fibrosis treatment market report, along with forecasts at the country and regional levels from 2025-2033. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Drug Class, End User, Region |
Region Covered | North India, West and Central India, South India, East India |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report: